DERMATOLOGICAL REACTIONS CAUSED BY ANTITUMOR DRUGS — EGFR INHIBITORS


Cite item

Full Text

Abstract

Published data on modern antitumor drugs, acting as epidermal growth factor receptor inhibitors, are pre sented. Their inevitable side effects — skin toxicity — are explained by their nature. Therapeutic approaches to management of these reactions are discussed and a clinical case is presented.

About the authors

Ekaterina Vadimovna Orlova

I.M.Setchenov First Moscow State Medical University

Email: kolip7@mail.ru
кандидат мед. наук Moscow, Russia

Olga Yurievna Olisova

I.M.Setchenov First Moscow State Medical University

Email: olisovaolga@mail.ru
доктор мед. наук, профессор Moscow, Russia

Lyudmila Yurievna Sevidova

I.M.Setchenov First Moscow State Medical University

кандидат мед. наук. Moscow, Russia

Nikolay Georgievich Kochergin

I.M.Setchenov First Moscow State Medical University

Email: nkocha@yandex.ru
доктор мед. наук, профессор Moscow, Russia

References

  1. Woodburn J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther. 1999; 82(3): 241—50.
  2. Weiner L.M. Fully human therapeutic monoclonal antibodies. J. Immunother. 2006; 29(1): 1—9.
  3. Lacouture M.E. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat. Rev. Cancer. 2006; 6(10): 803—12.
  4. Douillard J.Y., Siena S., Cassidy J. Randomized, phase III study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as first-line treatment for metastatic colorectal cancer (mCRC): the PRIME trial. Eur. J. Cancer. 2009; 7(Suppl. 3): abstr.10LBA.
  5. Peeters M., Price T., Hotko Y. Randomized, phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer (mCRC). Eur. J. Cancer. 2009; 7(Suppl. 3): abstr. 14LBA.
  6. Peeters M., Van Cutsem E., Siena S. et al. A phase 3, multicenter, randomized controlled trial of panitumumab plus best supportive care (BSC) vs BSC alone in patients with metastatic colorectal cancer. In: Program and abstracts of the 97th Annual Meeting of the American Association for Cancer Research. April 1—5 2006, Washington DC; Proc. Am. Assoc. Cancer Res. 2006; 47: abstr. CP-1.
  7. Mitchell E.P., Perez-Soler R., Van Cutsem E., Lacouture M.E. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. Oncology (Williston Park). 2007; 21(11, Suppl. 5): 4—9.
  8. Pilon M., Mailhot M., Comtois A. Evaluation of a protocol algorithm for the treatment of epidermal growth factor receptor inhibitors-induced dermatological side effects (Epiderm study). In: Presented at: 44th American Society of Clinical Oncology Annual Meeting. May 30—June 3, 2008; Chicago, IL. abstr. 20755.
  9. Ocvirk J., Rebersek M. Managing cutaneous side effects with K1 vitamine creme reduces cutaneous toxicities induced by cetuximab. In: Presented at 44th American Society of Clinical Oncology Annual Meeting. May 30—June 3, 2008; Chicago, IL. abstr. 20750.
  10. Activities of Daily Living. NCI-CTCAE V.4.0. http://ctep.cancer.gov.
  11. Van Cutsem E. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist. 2006; 11(9): 1010—7.
  12. Lacouture M.E., Mitchell E.P., Piperdi B., Pillai M.V., Shearer H., Iannotti N., et al. Skin oxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J. Clin. Oncol. 2010; 28(8): 1351—7. doi: 10.1200/JCO.2008.21.7828.
  13. Elez E., Macarulla T., Tabernero J. Handling side-effects of targeted therapies: safety of targeted therapies in solid timours. Ann. Oncol. 2008; 19(Suppl.7): vii146—52. doi: 10.1093/annonc/mdn476.
  14. Bosch J., Abella L., Viudez A., Chopitea A., Rodriguez J., Rodriguez J., et al. Clinical impact on time to progression (TTP) of acneiform skin lesions in cetuximab-based regimens in colorectal cancer. American Society of Clinical Oncology Annual Meeting Proceedings. J. Clin. Oncol. 2008; 26(15, Suppl.): abstr. 15096.
  15. O’Callaghan C.J., Tu D., Karapetis C.S., Au H.J., Moore M.J., Zalcberg J.R., et al. The relationship between the development of rash and clinical and quality of life outcomes in colorectal cancer patients treated with cetuximab in NCIC CTG CO.17. American Society of Clinical Oncology Annual Meeting Proceedings. J. Clin. Oncol. 2008; 26(15, Suppl.): abstr. 4130.
  16. Humblet Y., Peeters M., Siena S., Hendlisz A., Neyns B., Sobrero A., et al. Association of skin toxicity severity with clinical outcomes and health-related quality of life with panitumumab. American Society of Clinical Oncology Annual Meeting Proceedings. J. Clin. Oncol. 2007; 25 (18, Suppl.): abstr. 4038.
  17. Berlin J., Van Cutsem E., Peeters M., Hecht J.R., Ruiz R., Wolf M., et al. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): A pooled analysis of five clinical trials. American Society of Clinical Oncology Annual Meeting Proceedings. J. Clin. Oncol. 2007; 25(18, Suppl.): abstr. 4134.
  18. Douillard J.Y., Cassidy J., Jassem J., Rivera F., Kocáková I., Rogowski W., et al. Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment for metastatic colorectal cancer (mCRC): Efficacy by skin toxicity. American Society of Clinical Oncology Annual Meeting Proceedings. J. Clin. Oncol. 2010; 28(15, Suppl., Pt 1): abstr. 3528. www.ejconline.com

Copyright (c) 2013 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies